ATP7B expression in human glioblastoma is related to temozolomide resistance

Moinuddin,F. M.; Hirano,Hirofumi; Shinsato,Yoshinari; Higa,Nayuta; Arita,Kazunori; Furukawa,Tatsuhiko

doi:10.3892/ol.2017.7249

ATP7B expression in human glioblastoma is related to temozolomide resistance

Authors:
- F. M. Moinuddin
- Hirofumi Hirano
- Yoshinari Shinsato
- Nayuta Higa
- Kazunori Arita
- Tatsuhiko Furukawa
View Affiliations

Affiliations: Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890‑8544, Japan, Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890‑8544, Japan
Published online on: October 23, 2017 https://doi.org/10.3892/ol.2017.7249
Pages: 7777-7782
Copyright: © Moinuddin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma multiforme (GBM) is one of the most aggressive types of brain malignancy, with resistance to chemotherapy being a primary treatment obstacle. ATPase copper transporting β (ATP7B) is involved in multidrug resistance; however, its expression in GBM remains to be evaluated. In the present study, GBM specimens from 79 patients who underwent gross total tumor removal followed by concomitant temozolomide (TMZ) chemotherapy and radiotherapy were assessed immunohistochemically. The association between the overall survival times of patients and the expression of ATP7B in neoplastic cells was evaluated. In 12/79 tumors (15.2%) >10% of neoplastic cells were immunohistochemically‑positive for ATP7B, and categorized as high‑ATP7B GBM. In the remaining 67 tumors (84.8%) the rate of ATP7B‑positive cells was <10% and recorded as low‑ATP7B GBM. The median overall survival times of patients with high‑ and low‑ATP7B GBM were 14.6, and 24.7 months, respectively. High expression of ATP7B was identified to be associated with shorter overall survival times (hazard ratio, 0.452; 95% confidence interval, 0.206‑0.994; P=0.048). Of the 79 patients, 12 underwent a second operation due to recurrence. These tissue samples were also subjected to immunohistochemical study. The ATP7B positivity rate of tumor cells obtained during the second surgery was significantly higher compared with that in the first surgery (9.17±2.56 vs. 2.75±0.55%; P=0.008). In addition, two ATP7B‑transfected GBM cell lines were identified to be significantly resistant (3.8‑ and 1.7‑fold, respectively) to TMZ compared with the control cell line. The findings of the present study suggest that ATP7B influences GBM resistance to TMZ.

View Figures

View References

1	Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS and Villano JL: Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 23:1985–1996. 2014. View Article : Google Scholar : PubMed/NCBI
2	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
3	Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, Leenders WP and van Furth WR: Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer. 9:4442009. View Article : Google Scholar : PubMed/NCBI
4	Ohka F, Natsume A and Wakabayashi T: Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int. 2012:8784252012. View Article : Google Scholar : PubMed/NCBI
5	Moinuddin FM, Shinsato Y, Komatsu M, Mitsuo R, Minami K, Yamamoto M, Kawahara K, Hirano H, Arita K and Furukawa T: ATP7B expression confers multidrug resistance through drug sequestration. Oncotarget. 7:22779–22790. 2016. View Article : Google Scholar : PubMed/NCBI
6	Nakayama K, Kanzaki A, Terada K, Mutoh M, Ogawa K, Sugiyama T, Takenoshita S, Itoh K, Yaegashi N, Miyazaki K, et al: Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy. Clin Cancer Res. 10:2804–2811. 2004. View Article : Google Scholar : PubMed/NCBI
7	Kanzaki A, Toi M, Neamati N, Miyashita H, Oubu M, Nakayama K, Bando H, Ogawa K, Mutoh M, Mori S, et al: Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma. Jpn J Cancer Res. 93:70–77. 2002. View Article : Google Scholar : PubMed/NCBI
8	Ohbu M, Ogawa K, Konno S, Kanzaki A, Terada K, Sugiyama T and Takebayashi Y: Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human gastric carcinoma. Cancer Lett. 189:33–38. 2003. View Article : Google Scholar : PubMed/NCBI
9	Shinsato Y, Furukawa T, Yunoue S, Yonezawa H, Minami K, Nishizawa Y, Ikeda R, Kawahara K, Yamamoto M, Hirano H, et al: Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma. Oncotarget. 4:2261–2270. 2013. View Article : Google Scholar : PubMed/NCBI
10	Che XF, Zheng CL, Owatari S, Mutoh M, Gotanda T, Jeung HC, Furukawa T, Ikeda R, Yamamoto M, Haraguchi M, et al: Overexpression of survivin in primary ATL cells and sodium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines. Blood. 107:4880–4887. 2006. View Article : Google Scholar : PubMed/NCBI
11	Joshi K, Banasavadi-Siddegowda Y, Mo X, Kim SH, Mao P, Kig C, Nardini D, Sobol RW, Chow LM, Kornblum HI, et al: MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells. 31:1051–1063. 2013. View Article : Google Scholar : PubMed/NCBI
12	Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
13	Yang P, Zhang W, Wang Y, Peng X, Chen B, Qiu X, Li G, Li S, Wu C, Yao K, et al: IDH mutation and MGMT promoter methylation in glioblastoma: Results of a prospective registry. Oncotarget. 6:40896–40906. 2015. View Article : Google Scholar : PubMed/NCBI
14	Gao Y, Fotovati A, Lee C, Wang M, Cote G, Guns E, Toyota B, Faury D, Jabado N and Dunn SE: Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase. Mol Cancer Ther. 8:3276–3284. 2009. View Article : Google Scholar : PubMed/NCBI
15	Vulpe C, Levinson B, Whitney S, Packman S and Gitschier J: Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. Nat Genet. 3:7–13. 1993. View Article : Google Scholar : PubMed/NCBI
16	Bull PC, Thomas GR, Rommens JM, Forbes JR and Cox DW: The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet. 5:327–337. 1993. View Article : Google Scholar : PubMed/NCBI
17	Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, Romano DM, Parano E, Pavone L, Brzustowicz LM, et al: The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet. 5:344–350. 1993. View Article : Google Scholar : PubMed/NCBI
18	Davies KM, Hare DJ, Cottam V, Chen N, Hilgers L, Halliday G, Mercer JF and Double KL: Localization of copper and copper transporters in the human brain. Metallomics. 5:43–51. 2013. View Article : Google Scholar : PubMed/NCBI
19	Owatari S, Akune S, Komatsu M, Ikeda R, Firth SD, Che XF, Yamamoto M, Tsujikawa K, Kitazono M, Ishizawa T, et al: Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res. 67:4860–4868. 2007. View Article : Google Scholar : PubMed/NCBI
20	Miyashita H, Nitta Y, Mori S, Kanzaki A, Nakayama K, Terada K, Sugiyama T, Kawamura H, Sato A, Morikawa H, et al: Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin. Oral Oncol. 39:157–162. 2003. View Article : Google Scholar : PubMed/NCBI
21	Veringa SJ, Biesmans D, van Vuurden DG, Jansen MH, Wedekind LE, Horsman I, Wesseling P, Vandertop WP, Noske DP, Kaspers GJ and Hulleman E: In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PLoS One. 8:e615122013. View Article : Google Scholar : PubMed/NCBI
22	Henson JW, Cordon-Cardo C and Posner JB: P-glycoprotein expression in brain tumors. J Neurooncol. 14:37–43. 1992. View Article : Google Scholar : PubMed/NCBI
23	Sawada T, Kato Y, Sakayori N, Takekawa Y and Kobayashi M: Expression of the multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors. Brain Tumor Pathol. 16:23–27. 1999. View Article : Google Scholar : PubMed/NCBI
24	Daood M, Tsai C, Ahdab-Barmada M and Watchko JF: ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics. 39:211–218. 2008. View Article : Google Scholar : PubMed/NCBI